Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Shares Outstanding (Diluted Average) (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Shares Outstanding (Diluted Average) for 11 consecutive years, with $77.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 910.35% to $77.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $77.8 million through Dec 2025, up 910.35% year-over-year, with the annual reading at $77.8 million for FY2025, 910.35% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $77.8 million at Plus Therapeutics, up from $57.8 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $77.8 million in Q4 2025, with the low at $1.5 million in Q2 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $14.7 million, with a median of $7.6 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) tumbled 89.21% in 2023, then skyrocketed 910.35% in 2025.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $13.3 million in 2021, then crashed by 86.8% to $1.8 million in 2022, then skyrocketed by 79.45% to $3.1 million in 2023, then surged by 145.18% to $7.7 million in 2024, then surged by 910.35% to $77.8 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $77.8 million, $57.8 million, and $24.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.